Literature DB >> 7832187

Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.

K Okajima1, H Abe, M Wagatsuma, H Okabe, K Takatsuki.   

Abstract

Abnormal antithrombin III (AT III) was found in a 30-year-old woman who suffered from recurrent thrombosis during pregnancy and the postpartum period. Among her family members, only her father had recurrent episodes of deep vein thrombosis of the lower extremities, from his youth. The antithrombin and antifactor Xa heparin cofactor activities of the proposita's plasma were 61% and 42% of normal, respectively. The progressive antithrombin and antifactor Xa activities were also decreased to 55% and 58% of normal, respectively. The immunoreactive level of AT III was within the normal range (23.1 mg/dl). Analysis of the proposita's plasma by crossed immunoelectrophoresis in the presence or absence of heparin and by affinity chromatography on heparin-Sepharose revealed that the proposita's AT III had apparently normal affinity for heparin. Nucleotide sequencing of 7 exons of the proposita's AT III gene amplified by polymerase chain reaction (PCR) disclosed that the second base of codon 393 comprised both G and A, indicating Arg393-His conversion. The base sequences of exons 1, 2, 3a, 3b, 4, and 5 were normal, excluding any other mutation. These findings indicated that the proposita's AT III was a variant of AT III at the thrombin binding site and that the proposita was a heterozygote for the abnormality. Heparin affinity of purified abnormal AT III from the proposita's plasma was demonstrated to be increased upon affinity chromatography using heparin-Sepharose, suggesting that the mutation (Arg393-His) per se could possibly increase the affinity of antithrombin III for heparin. For this variant AT III (Arg393-His), the name AT III Kumamoto II is proposed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832187     DOI: 10.1002/ajh.2830480104

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  The genetics of venous thromboembolism: a systematic review of thrombophilia families.

Authors:  Yu Zhang; Zhu Zhang; Shi Shu; Wenquan Niu; Wanmu Xie; Jun Wan; Zhenguo Zhai; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

2.  Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism.

Authors:  Mana Mitsuguro; Toshiyuki Sakata; Akira Okamoto; Sachika Kameda; Yoshihiro Kokubo; Yoshiaki Tsutsumi; Michitaka Sano; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

Review 3.  Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer.

Authors:  Khue Vu Nguyen
Journal:  AIMS Neurosci       Date:  2022-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.